UK research partners team up to accelerate MND drug discovery
Drug Discovery World
JUNE 5, 2024
million to fund a new two-year collaborative partnership with King’s College London (KCL) to validate a portfolio of human genetic driven therapeutic targets for motor neuron disease (MND). The proposed programme uses bioinformatics approaches and experimental models to validate and de-risk a portfolio of potential MND therapeutic targets.
Let's personalize your content